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PharmacodynamicsChildren deserve medicines that are adapted to their needs. The need to include children in drug development
has been recognised increasingly over the past few decades. Legal and regulatory frameworks are well
established in the EU and US. The amount of work done to study medicines for children is signiﬁcantly greater
than it was 10 years go. Proof-of-concept has been demonstrated for all segments of the paediatric drug devel-
opment pipeline. It is now time to examine how the practice of developing medicines for children has evolved
within those frameworks and to determine how that work should be generalised. This review describes the de-
velopment of medicines for children and critically appraises the work that has been done within those frame-
works. Signiﬁcant effort is needed to realize the potential provided by the current regulatory framework. Using
thework programmeof theGlobal Research in Paediatrics (GRiP) Network of Excellence as a templatewe outline
current work and future growing points.
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Everyone deserves medicines that meet their needs. All medicines
need to be given at the correct dose, with an acceptable risk beneﬁt pro-
ﬁle. Medicines should be of good pharmaceutical quality with legally
enforceable quality assurance of all aspects of their development and
use.
In the past children were largely denied access to appropriate
medicines that meet these criteria. Historically, children have not re-
ceived medicines that have been rigorously evaluated and have been
given medicines designed for adults. When medicines are adapted
for children this is often done informally and in the absence of
evidence, using measures such as cutting pills in half [1]. In the
past decade signiﬁcant attention and effort have been directed to
overcome the gaps in medicines provided to children. A clear expec-
tation that children will havemedicines that meet their needs is now
established.
Legislative and regulatory frameworks to underpin the expectation
that children will be given the medicines they deserve are now
established in twomajor jurisdictions (EU and USA). These frameworks
are no longer “new” ways of doing things. The outlines of how to pro-
vide appropriate medicines to children are well established. The drug
development community needs to work within those outlines. Future
work needs to optimize the existing frameworks and develop the best
ways to work within those frameworks.2. Background: children need adapted medicines and speciﬁc
approaches to drug development
Children differ from adults in a number of ways that are relevant to
the development and use of medicines. These differences include the
ways in which medicines are adsorbed, distributed, metabolized and
excreted by the body (pharmacokinetics) and what medicines do to
the body (pharmacodynamics) [2]. Children are often unable to take
the dosage forms that are designed for adults. For example, tablets
that allow for adult doses may need to be split before being given to
younger children, based on an undemonstrated assumption that the
distribution of the active substance within the tablet is uniform. The ef-
fects of such manipulations are poorly documented [1]. In the past, and
unfortunately still today, a large proportion of medicines were given to
children in an “off label” manner, or even without a license/marketing
authorisation [3]. Clinical practice was deﬁned by extrapolating datafrom adults without testing medicines in children [3]. The data used to
do this were not necessarily gathered from adults being treated for
the same indication (or the same disease). There could be little evidence
derived from pharmacokinetic, dose ﬁnding, or formulation studies
properly conducted in the paediatric population. Inadequate testing
can expose children to a direct risk of under or overdosing and a delayed
risk of long term adverse effects.
Moreover diseases in children are often different from their adult
equivalents. The processes underlying growth and development might
lead to a different effect and response to drug unseen in adults. Particu-
larly, children at various ages might be exposed to different risk/beneﬁt
ratios. Thus, children are not small adults. Indeed, pharmacologically
speaking infants are not small children. Important medicines need to
be tested in each target population [3].
In the pastmarket forces alonewere not a sufﬁcient incentive for ad-
equate research and development of paediatric medicines. Paediatric
development has depended to a considerable extent on the pharmaceu-
tical company's product strategy with respect to the adult population.
For many companies adults represent the most economically attractive
market. Paediatric strategies are often driven by the incentives relating
to adult markets rather than the needs of children. Exceptions to this
generalisation include vaccines and medicines for indications only
found in children. Regulatory and scientiﬁc international collaborations
are needed because they can favour global paediatric development
programmes, and consequently make paediatric research more effec-
tive, efﬁcient, ethical and quality well conducted. Recently, it has be-
come widely recognised that children and young people and their
parents and caregivers must be at the heart of research planning and
conduct. Regulators such as the EuropeanMedicines Agency (EMA) de-
veloped frameworks for the involvement of children and young people
in their work [4].3. Legislative and regulatory frameworks
Children have been often referred to as “therapeutic orphans” who
are exposed to avoidable risks while missing out on therapeutic
advances [5]. Children have suffered from a lack of testing and authori-
sation of medicines for their use, despite the fact that the pharmaceuti-
cal legislative framework, ensuring the high standards of safety, quality
and efﬁcacy of medicinal products for use in adults, was developed pri-
marily in response to past “drug disasters”, mainly involving children
(e.g. sulphanilamide and thalidomide tragedies), reviewed in [3].
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then in Europe has signiﬁcantly changed the worldwide legislative
frameworks.
3.1. ICH
The ﬁrst joint paediatric regulatory action was taken in the context
of the International Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH), an
organisationworking on the harmonisation of pharmaceutical regulato-
ry requirements between the EU, Japan and theUS in July 2000with the
adoption of the ICH E11 guideline [6]. The goals were to encourage and
facilitate timely paediatric drug development internationally and to
provide an outline of critical issues in paediatric drug development
and approaches to the safe, efﬁcient and ethical study of medicines.
The ICH E11 guideline became a valuable instrument in designing pae-
diatric clinical research worldwide; however, the guideline is a recom-
mendation, not a mandatory requirement, thus it had practically no
effect on paediatric submissions in Europe andworldwide: for example,
between 1995 and 2005, 44% of the 243 medicines authorised by the
EMA had a potential paediatric use but no data available [7]. Due to
advances in the knowledge and understanding of paediatric medicine
development an update of this guideline is necessary and some initial
work has been started in this context.
3.2. US FDA regulatory initiatives
The ﬁrst regulatory initiatives based mainly on a voluntary process
were launched successfully by the US FDA in the 1990s and early
2000s, and afterwards amended and reauthorized in 2007 as related
sections of the Food and Drug Administration Amendments Act
(FDAAA). Title III or the Pediatric Medical Device Safety and Improve-
ment Act, Title IV or Pediatric Research Equity Act (PREA) and Title V
or the Best Pharmaceuticals for Children Act (BPCA) all afﬁrmed the pri-
ority of appropriate development of products intended for use in chil-
dren. Title V of FDAAA (BPCA) codiﬁed a voluntary process initially
included in the PrescriptionDrugUser Fee Act of 1997 then subsequent-
ly renewed in the BPCA of 2002 where FDA would deﬁne the pharma-
ceutical products which needed paediatric studies based on perceived
public health impact, outline the necessary studies, and issue a Paediat-
ricWritten Request to Sponsors. If the Product Sponsor submitted stud-
ies responding to the Paediatric Written Request, six additional months
of marketing exclusivity were granted. The BPCA provision of FDAAA
renewed the exclusivity incentives, strengthened a process for research
into off patent medicines involving government contracts for paediatric
studies, and mandated public disclosure of the study results. PREA ex-
tended the mandate programme to perform studies in children for
products developed for adults that meet certain criteria based on public
health impact. The provisions of BPCA and PREA have recently been
made permanentwith the Food and Drug Administration Safety and In-
novation Act (FDASIA) [8]. FDASIA has reconﬁrmed the PREA principle
of an expectation for a paediatric study plan (PSP) for products that
are the subject of a marketing application if the application relates to a
new active pharmaceutical ingredient, a new formulation, a new
indication or a new dosing regimen or route of administration [9]. As
in the past, mechanisms for requesting waivers or deferrals for some
or all paediatric age groups are included.
3.3. EU regulatory initiatives
The need to include children in drug developmentwas implicitly in-
cluded in European legislation for some time [10]. These measures did
not provide the information needed for the majority of medicines
[11–14]. At the end of 2006, an EU Paediatric Regulation (Reg 1901/
2006/EU and Reg 1902/2006/EU) was adopted with a similar scope
and a different implementation mechanism than the US legislation.Like the US legislation, the goals focus on improving children's health
through advancements in research and on providing a new framework
for an efﬁcacious and safe use of paediatric drugs. Similar to the system
in place under FDASIA, the EU Paediatric Regulation is expected to lead
to faster and more profound changes since paediatric development has
become mandatory for all new “unauthorised” drugs under develop-
ment and for any variations of patented authorised medicines, unless
a waiver is granted.
An important contrast between the framework in the EU and the
USA is the timing of the paediatric development plan. The European
PIP should be agreed at the end of Phase 1 while the American PSP
should be agreed at the end of Phase 2. The theoretical advantages for
early engagement are often outweighed by the fact that studies includ-
ed in PIPs are deferred for considerable periods. Global development
would beneﬁt from a harmonised approach across the two jurisdictions.
Even if it brings higher requirements to industry, the Paediatric Reg-
ulation retains the principle of rewards (an extra 6 months of patent
protection, i.e. extension of the duration of its Supplementary Protection
Certiﬁcate [SPC]), for unauthorised and/or patented medicines and an
extra two years of market exclusivity for orphan medicinal products;
it requires agreement with the Paediatric Committee (PDCO) on the
paediatric development and compliance with the agreed paediatric in-
vestigation plan (PIP) before applying for the marketing authorisation
for all unauthorised and/or patented medicines, including type II MA
variations; interestingly, the paediatric development is required to
cover all paediatric age subsets, from neonates to the adolescent, in all
paediatric and adult conditions, with an age-appropriate formulation.
In some cases, studies can be deferred until after the studies in adults
have been conducted. This ensures that research in children is done
onlywhen it is safe and ethical to do so. On the other hand the uncritical
use of deferrals can lead to unnecessary delays. In some conditions the
beneﬁt–risk balance is in favour of conducting studies in children and
neonates early in the adult development programme. Deferral can also
mean that paediatric studies are planned after patent expiry which
may be a risk for companies or lead to the studies not being done.
Even when studies are deferred, the PIP has to include details of the
paediatric studies and their timelines. Moreover, as some diseases do
not affect children (for example Parkinson's disease), a PIP is not
required and it can be waived.
Finally the Paediatric Regulation has also established a new type
of marketing authorisation (not foreseen by the US legislation),
called the Paediatric Use Marketing Authorisation (PUMA), intended
to stimulate the development of off-patent products for use in the
paediatric population (most of these compounds are widely used
daily in children of all age groups and mostly not adequately tested
in this population). PUMA guarantees a 10 (8 + 2) year data
protection.3.4. Other legislations
Very few legislative and regulatory initiatives have been undertaken
in countries other thanUSA and Europe. In Canada, a 6 month extension
for data protection is granted to innovator companies providing evi-
dence to support a paediatric label indication. In Japan, there is no com-
prehensive legislation to provide incentives and mandate development
of paediatricmedicines. In 2010, a programmewas introduced as part of
the new drug development promotion scheme: a price premium for
promotion of new medicines, and creation and resolution of unap-
proved/off label medicines. As of February 201,1 the development of
60 unapproved medicines and 122 off-label indications has been re-
quested by the Ministry of Health, Labour and Welfare (MHLW). In
Australia, despite many paediatric speciﬁc medicine initiatives through
professional and government advisory bodies, formal legislative and
regulatory reforms addressing paediatric medicines are still missing
[15].
5M.A. Turner et al. / Advanced Drug Delivery Reviews 73 (2014) 2–13Finally, WHO launched an initiative ‘Making Medicines Child Size’ in
2008 to issue a list of essential medicines for children, advocating the
paediatric development of and access to appropriate quality medicines
especially for emerging countries: http://tinyurl.com/82knoar.
The next sections present a review of the impact of the US and EU
legislation. The focus is on publications associated with the FDA and
EMA, with some other papers cited when appropriate.
4. The achievements and impact of legislation in US and EU
Each of the major jurisdictions had reviews of progress during
2011–12.
In EU this included a report from the European Commission about
the impact of the Paediatric Regulation during the ﬁve years after its im-
plementation [16]. This was informed by a report from the EMA [17]
and supported by a consultation with stakeholders [18]. Five years is
enough to look at process but not impact. An impact assessment of
10 years after the implementation of the EU legislation is planned;
this will include economic aspects. A similar exercise was conducted
in the US. The Institute of Medicine examined the impact of American
legislation [19]. The data presented in those reviews is based on data
routinely collected by the regulators. This was supplemented by inter-
pretative work bymembers of the agency and expert assessors. A num-
ber of general reviews have been published [3,7,20–23]. Book length
descriptions of the issues in paediatric drug development include a
summary of key aspects of drug development [24] and an overview of
regulatory aspects [25].
Some of the data about the impact of regulations are comparable
across jurisdictions. Other aspects of the reports are complementary.
In either case the literature provides an important opportunity to look
at the impact of legislation in a semi-quantitative way. A full impact as-
sessment will require health economic data and will only be possible
once the legislation has had the chance to inﬂuence the life cycle of a
considerable number of medicines. In essence, the “regulatory revolu-
tion” seen in the past decade has demonstrated proof of concept that
it is possible to develop medicines for children in a way that beneﬁts
children andmeets the needs of all relevant stakeholders. The following
sections indicate which aspects of that concept have been proven and
which aspects need further development. The impact and achievement
of each element of the regulatory frameworks are considered in turn.
4.1. Overview
There has been a signiﬁcant increase in the number of medicines
with information relating to children. The FDA examined a source fre-
quently used by US clinicians to support prescribing, the Physician's
Desk Reference [26]. In 1999, 20% of new medical entities relevant to
paediatrics had paediatric information while between 2002 and 2008
41% had paediatric information. In 1973 this publication had paediatric
information on 22% of products and in 2009 the ﬁgure was 46% [26].
The regulatory frameworks have improved our understanding of a
number of medicines used in children. This is illustrated by an FDA
report on labeling changes relating to children made between 1998
and 2005. Of 108 products (somewith more than one labeling change),
23 had dosing changes or new PK data, 34 had new information about
safety, 19 had information about a lack of efﬁcacy in at least some con-
ditions while 77 broadened the age range for on-label use and 12 had a
new formulation. Of 16 case studies examining pharmacokinetics, ﬁve
had lower clearance than expected on the basis of body weight, four
had higher than expected clearance and four had clearance that
reﬂected weight [27].
4.2. Paediatric development plans
Herewe describe paediatric plans (a generic term to cover EU paedi-
atric investigation plans, PIPs, and US paediatric study plans, PSPs).In the US, between July 1998 and September 2011, the FDA
approved 500 labeling changes of which 453 were related to studies
requested under BPCA or required under PREA.
Between the implementation of the EU Paediatric Regulation and
the end of 2011, the PDCO had made decisions about 682 PIPs and 29
PIPs had been completed. Of these, 24 led to new paediatric indications
(for 24 medicines) and 77 for new formulations. Another 5 PIPs were
completed but the information did not support the use in children.
This information can be included in the product information and indi-
cated that the PIP process can lead to decisions not to use medicines
in children. To date there has been one successful application for a
Paediatric Use Marketing Authorisation (PUMA).
The main incentive under the regulation is a 6 month extension of
the Supplementary Protection Certiﬁcate by the National Patent Ofﬁces.
This has been granted in at least one Member State for 11 medicines.
It is clear that children were neglected during drug development in
the past. The EMA has estimated that before the Paediatric Regulation
came into force 34% of medicine authorisations included a paediatric
indication, 23% of medicines were not useful for children and 43% of
medicines could be relevant to children but data relating to children
were not included in the materials submitted to support a Marketing
Authorization. As of the end of 2011 30% of applications for medicine
development had been deemed not relevant to children (through the
grant of a waiver by the PDCO). The remaining new medicines are
now all included in PIPs. There has been a signiﬁcant expansion in the
scope of research about medicines for children.
4.3. Neonates
One example of the way legislation can promote much needed re-
search is the inclusion of neonates in drug development plans. Neonates
are particularly vulnerable and more likely to have developmentally
mediated differences in drug disposition and effects. As of the end of
2011, 395 opinions from PDCO were potentially relevant to neonates
(not products related to allergens or products with a full waiver in the
paediatric age group). Of these, 60 (15%) PIPs submitted by companies
included studies on neonates with a waiver sought in the other cases.
The PDCO added measures for neonates to 50 PIPs (13%) meaning that
110 (28%) of potentially relevant PIPs included studies in neonates.
The studies included in PIPs were tailored to speciﬁc features of the
indication in neonates. For example, of 110 PIPs involving neonates,
47 (43%) included controlled trials of safety and efﬁcacy and 57% of
neonatal plans relied on extrapolation of efﬁcacy from older age groups.
58 neonatal PIPs (53%) included PK (PD) and tolerability studies and 24
(22%) included non-controlled safety and efﬁcacy studies (PIPs can
include more than one type of study). In contrast, the FDA reports that
between 1998 and 2010 there were 365 labeling changes relating to
children. These included 23 (6%) that involved studies recruiting
neonates. The predominant neonatal condition which was affected by
labeling change was infection, changes were also made to medicines
relevant to neonatal gastroenterology, cardiology and anaesthesia
[19]. The relative neglect of neonates since the initiation of regulatory
initiatives targeting children has been highlighted by a study of FDA da-
tabases [28].
The needs of neonates are not beingmet. Thismay be due to a lack of
newmedicines that can be inﬂuenced by regulatory processes. Neonatal
markets are relatively small and “legacy”medicines arewidely used and
cheap so that companies may not have sufﬁcient incentives to develop
newmedicines for existing indications. On the other hand, a large num-
ber of waivers have been allowed by the PDCO and FDA has not been
able to consider neonatal data sets for many proposed labeling changes.
The waiver pathway was intended to avoid unnecessary research.
When applied to neonates it suggests that companies and the PDCO be-
lieve that the beneﬁt–risk balance of manymedicines is unfavourable. It
is possible that these decisions are more risk averse than they need to
be. A lack of information about medicines is more likely to be harmful
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beneﬁcial.
4.4. Off patent medicines
In the EU the Regulation provided funding to support research into
off patentmedicines through Framework Programme7. To date, 19 pro-
jects involving at least 24 off patent medicines have been funded. In the
USwork on/off patentmedicines is funded by theNIH and administered
through the Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD), through a Pediatric Trials Network.
Both jurisdictions have processes to prioritise research into off patent
medicines. In Europe this is done by the EMA and PDCO [29].
The EMA has also published lists of needs relating to medicines in
children [30].
In the US this is done by the NICHD with consultation by the FDA,
subject matter experts and the public [31].
4.5. Extrapolation
There is an ethical requirement tominimize the number of studies in
children and the number of children recruited to studies. Children are
not able to consent for themselves and in many cases can be more vul-
nerable to the effects of studies than people in older age groups. One
way to meet this requirement is to extrapolate from data about the
drug and the condition from older age groups. This approach is outlined
in regulatory guidance, for example ICH E11 [6]. A baseline for the use of
extrapolation in the development of medicines for children is provided
by a review of updates to drug status provided by 95 EPARs between
1995 and 2007. These authors concluded that 66% of the studies were
required, 22% could have been done more appropriately if all relevant
data had been used to develop a well-designed extrapolation study
and 12% of studies were judged to be unnecessary [32].
The use of extrapolation studies has been reviewed by the FDA who
was able to use extrapolation (partial or complete) in a majority of
studies [33].
When the 210 PIP opinions given by the PDCO until January 2010
were reviewed, it was found that 47 (22%) of opinions included model-
ing and simulation. Some of this was for bridging and other cases were
designed to optimize the development process, for example through
dose selection. FDA has reported case studies of modeling in paediatric
PK dosing [34] and other contexts [35].
The complexities of assessing whether extrapolation is required are
provided by Piana et al. [32]. Further work is needed to provide a sys-
tematic approach to extrapolation. Central to extrapolation is the expo-
sure/response relationship (E/R) which needs to be developed in adults
if bridging is to be done [32]. EMA has stimulated discussion about this.
One approach is to consider when extrapolation is possible and useful
[36]. This can be extended by examining which data is useful in a
range of scenarios [37]. At the time of writing EMA is examining the
best approaches to extrapolation in drug development and, after a pub-
lic consultation, has released a “Concept paper on extrapolation of
efﬁcacy and safety in medicine development” (EMA/129698/2012),
aimed at developing a framework for an explicit and systematic ap-
proach which sets out when, to what extent, and how extrapolation
can be applied andwhich includes many examples for paediatric devel-
opment. [38].
4.6. Timing
The progress of paediatric plans is difﬁcult to assess using publicly
available data. Some types of plans have to submit annual progress
reports in the EU. Up to the end of 2011 the EMA had received 91 of
these annual reports. Among these reports, 21 reported delays with
recruitment, 11 reported delays with ethics or regulatory approvals, 6
had concerns with safety and 3 with efﬁcacy. A review of the progressof paediatric studies required under the US PREA legislation showed
that up to “78% of drug studies and 54% of studies on biological products
(such as vaccines) were either not completed or were ﬁnished late”,
compared to their due date in 2007 ([39] citing Dr Fraterelli). This
topic is speciﬁcally addressed in the FDASIA of 2012 with enhanced
tracking requirements.
Most of these delays are due to avoidable, organizational issues. Re-
cruitment can be optimized through well-organised clinical research
networks with strong performance management. Adequate recruit-
ment requires appropriate targets that can only be set accurately in
the light of good feasibility data. Feasibility data should inform the
development of paediatric plans as well as individual protocols. Issues
with ethics and other regulatory groups often stem from lack of
awareness of the relevant procedures. Previous experience of these
procedures can shorten trial setup times considerably. The need to
“reinvent the wheel” slows down many sponsors when they address
paediatric studies for the ﬁrst time. An effective way to address recruit-
ment and regulatory issues is to use pre-existing clinical research
networks that provide reusable infrastructure and generic expertise.
The development of competent and efﬁcient clinical research networks
is a priority if the potential of the regulatory environment is to be
realized.
4.7. Modiﬁcations
By the endof 2011,when 513 PIP opinions had been given, there had
been 315 opinions about modiﬁcations to PIPs. A sample of 100mod-
iﬁcations was examined. Timelines were changed in 59 of 100 mod-
iﬁcations, of which 31 were changes of less than 1 year and 28 were
changes of more than one year. Delays were reported in 61% of these
reports. Changes to dosing recommendations were found in 9% of the
modiﬁcations and changes to inclusion criteria and secondary out-
comes were found in 9% of the modiﬁcations.
4.8. Preclinical
The European Regulation includes consideration of animal studies. A
guideline has been issued by the EMA [40] and reviewed in [41].
The experience of the EMA pre clinical working group has been de-
scribed [42] using a sample of 97 PIPs submitted between November
2008 and May 2010. Juvenile animal studies were planned, or had
been completed, by the applicant in 33% of the 97 PIPs. The non-clinical
working party recommended additional studies in 26% of the cases.
Triggers for juvenile animal studies included a target population aged
less than 2 years. The EMA had particular concerns about whether reac-
tions would be reversible and potential effects on the reproductive
system that would only be apparent after puberty and in later life
[42]. A review has examined PIP decisions between 2007 and 2009
[43]. In total 50 of 205 (24%) of PIPs included juvenile animal studies.
The number of proposed studies was 87 with 60 of them (69%) involv-
ing juvenile rats.
The FDA reported some illustrative case studies of the value of stud-
ies in juvenile animals [44]. Over time there was a tendency to reduce
the use of two species in juvenile testing and use of study designs that
examined speciﬁc questions about toxicity that had been raised by
adult studies (human and animal) or mechanisms that are speciﬁc to
children. These examples include more targeted safety information,
and novel signals. This provided a rationale for setting the lower age
limit for paediatric use in some cases. In other cases, the ﬁndings were
reassuring and potential safety issues could be de-emphasized in subse-
quent development [44].
4.9. Use of existing data
Article 45 of the European Paediatric Regulation prompted market-
ing authorisation holders to share studies with the EMA. More than
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Regulation) were submitted, covering c.1000 active substances. The
National Competent Authorities (NCAs) have shared the assessment of
these studies. By the end of 2011, 149 active substances had been
reviewed, leading to changes in 65 Summaries of Product Characteris-
tics (SmPCs; labeling information).
Meanwhile, up to September 2011, 318 studies (completed after the
entry into force of the Paediatric Regulation) have been submitted
(Article 46) and 25 assessment reports for nationally authorised medi-
cines have been published.
Articles 45 and 46 of the EU Paediatric Regulation resulted to be a
valid tool for gathering fragmented and sparse considerable amount of
paediatric information that existed at company level, and for
recommending and implementing changes to the SmPCs of authorised
products. However, there still remains reluctance bymarketing authori-
sation holders to start this update process on a voluntary basis.
4.10. Collaboration between regulators
Joint working between regulators has been increasing since the
foundation of a Pediatric Cluster by members of the paediatric medi-
cines team at the EMA and the Ofﬁce of Pediatric Therapeutics at the
FDA. This allows discussion of paediatric plans as well as general issues
in regulatory science. The Japanese and Canadian agencies are also
involved in these discussions. The EMA, the FDA and the NICHD are
members of the World Health Organization's Paediatric Medicines
Regulators' Network (PmRN): http://tinyurl.com/7l77pbs and the
FP7 Network of Excellence, Global Research in Paediatrics (GRiP):
http://tinyurl.com/ozv863z.
4.11. Links between regulators and investigators
The EU Regulation included a unique provision to set up a network
of paediatric clinical research networks that support clinical trials of in-
vestigational medicinal products. The European Network for Paediatric
Medicines Research at the European Medicines Agency (EnprEMA)
was established in 2009. EnprEMA allows a dialogue between PDCO
and networks [45]. Networks represent investigators and have been
accredited using the criteria developed by networks and summarised
on the EnprEMA website [46]. EnprEMA bridges between industry and
networks to ﬁnd centres. It has also supported the development of
model PIPs and is promoting participation in clinical trials. It is clear
that there are a lot of good practices among paediatric clinical research
networks, which need to be disseminated. Regulators have collaborated
with investigators to develop guidelines for trials and summarise regu-
latory issues in a number of therapeutic areas includingHepatitis C [47],
obesity [48] and psychopharmacology [49–51]. There has been some
collaboration between regulators, researchers and industry to develop
a shared understanding of rational drug development: http://tinyurl.
com/qge5bkg.
Examples include products for speciﬁc immunotherapy of allergens
[52]. Overall, thisﬁtswith the claims of regulators tohave a proactive at-
titude [53].
In the United States, links between regulators and investigators are
direct and indirect. Direct linkage is through advisory committees that
meet with regulators to provide input. Examples include a Pediatric Ad-
visory Committee and subspecialty focused Pediatric Oncology Subcom-
mittee that reports to the Oncological Drugs Advisory Committee. In
addition, investigators and regulators meet through ad hoc meetings
about speciﬁc products. Paediatric device development is supported
through a consortium supported by the FDA Ofﬁce of Orphan Drug
Products and all product types can be supported by individual pro-
gramme grants through the same ofﬁce.
Indirect linkages occur through the NIHwith a joint NIH–FDA initia-
tive to periodically develop a priority list plus NIH support of a PediatricTrials Network to generate data primarily in response to Written
Requests for off patent medications.
4.12. Growth points in regulatory science
Regulatory science can be deﬁned as “the science of developing new
tools, standards, and approaches to assess the safety, efﬁcacy, quality,
and performance of products requiring approval by national or suprana-
tional competent authorities” (adapted from http://www.fda.gov/
ScienceResearch/SpecialTopics/). This section summarises a selection
of aspects of regulatory science which have been stimulated by the
legislation.
Regulators can provide unique insight into the utility of different as-
pects of trial design by examining studies frommore than one develop-
ment programme. For example Sun et al. reported that enrichment for
subjects with long lasting migraine attacks did not overcome the
high placebo response rates seen in migraine trials, while the non-
randomisation of patients who had an early placebo response was suc-
cessful for at least onedrug [54]. Benjamin et al. examined paediatric tri-
als of antihypertensive and found that trials were more likely to show
aneffect if they compared large differences in doses, used paediatric for-
mulations and used diastolic rather than systolic blood pressure as the
primary outcome [55]. Smith et al. examined safety in placebo groups
of trials of antihypertensives [56]. Ten trials submitted to FDA between
1998 and 2005 included a total of 1707 children in placebo arms. There
was no difference in AE rates. There were only 5 SAEs in the 10 trials.
None were related to the study drug and there was only one among
the participants allocated to placebo. These are useful data in discus-
sions about the role of placebos in trials that recruit children [56].
One way to maximise the value of recruiting children to trials is
through pooling data across drug development programmes. A good ex-
ample of this from within the FDA is a systematic review of 110 con-
trolled clinical trials of long acting beta agonists including 60,954
participants [57]. Adverse outcomes associated with long acting beta
agonists were more common in children than in adults. Allocation to
regular inhaled steroids appeared to mitigate the risk associated with
long acting beta agonists [57]. In addition to providing a speciﬁc mes-
sage for clinicians and investigators, this study shows proof of principle
for regulator led meta-analysis. FDA has contributed to similar studies,
e.g. reporting the incidence of cough in children receiving angiotensin
converting enzyme inhibitors or angiotensin receptor blockers [58]. An-
other study identiﬁed racial differences in response to antihyperten-
sives [59]. Regulators are not sufﬁciently resourced to pool studies
comprehensively. Many clinical researchers wouldwelcome the oppor-
tunity to be part of such studies, with appropriate safeguards about
conﬁdentiality and conﬂicts of interest. Systematic reviews and sponta-
neous reports from a National Competent Authority have been used to
develop proportionate pharmacovigilance in trials [60]. A major
challenge is the routine use of proprietary data standards by regulated
industry, the absence of consistent terminology and outcome deﬁni-
tions, and the subsequent need to map and convert individual data
sets to a common analytic data set for each meta-analysis.
4.13. Pharmaceutical quality
The European Regulation includes speciﬁc requirements for compa-
nies to develop age appropriate formulations. EMA reports that PIPs
have included relevant work. There have been a lot of discussions
about the safety of excipients and about how formulations will be
adapted to ensure that they are relevant to the needs of children. The
Formulations Working Group of the PDCO analysed 84 PIPs. A total of
125 pharmaceutical forms were proposed in these PIPs, of which 102
(82%) led to discussions of excipients. These discussions related to the
justiﬁcation of excipients, the dosage of excipients and the potential to
avoid excipients through alternative formulations. Testing for palatabil-
ity and acceptability was requested in 50% of the proposed dosage
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problematic for 23% of the formulations.
The EMA has recently published a guideline for pharmaceutical
development in children [61]. This work is supported by Paediatric For-
mulation Initiatives in the US [62] and EU [63]. Excipients are discussed
elsewhere in this issue.4.14. Guidelines
A number of guidelines and recommendations have been published.
The EMAmaintains awebpage for paediatric guidelines [64]. A num-
ber of workshops have been held: http://tinyurl.com/qge5bkg. Some
standard PIPs have been developed [65]. The FDAdatabase of guidelines
can also be consulted [66].4.15. Support for companies
The PDCO has contributed to Scientiﬁc Advice about 70 times a year.
The FDA offers presubmission meetings with the relevant review divi-
sion. In both cases, these procedures offer valuable opportunities to
streamline the regulatory process.
Moreover, EMA regularly organises workshops, not binding for
PDCO, on topics related to paediatrics aimed at providing general guid-
ance for paediatric development: http://tinyurl.com/qge5bkg.4.16. Economic return
There can be a signiﬁcant economic return from theUS incentives for
paediatric drug development. In one study 9 programmes that were
submitted for 6 months of additional exclusivity as a result of studies
in children, “paediatric exclusivity”, reﬂecting a range of therapeutic
areas between 2002 and 2004were selected for detailed economic eval-
uation. Among the 9 programmes net economic return of the 6 months
of paediatric exclusivity ranged from− $8.9 million to $507.9 million
and the net return to cost ratio ranged from−0.68 to 73.63 [67]. A sub-
sequent study examined 9 orally administered antihypertensive agents.
For these agents, the net economic return to cost varied between 4 and
64.7, with an average of 17 [68]. Thus for at least some agents an addi-
tional 6 months of exclusivity can be proﬁtable. It has been argued
that the regulatory frameworksmay not be economic for small tomedi-
um sized enterprises (SMEs) working with medicines that are not
blockbusters [49].
One important goal of the EU is to support small and medium sized
enterprises (SMEs). The Paediatric Regulation included provisions for
industry, including SMEs, with fee exemptions, deferrals and reduc-
tions. The EMA has developed an SME ofﬁce. By the end of 2009, more
than 170 SMEs had beneﬁtted from regulatory assistance with 130 re-
quests for scientiﬁc advice. Fee reductions to that date had totalled
€6.9 million [69].4.17. Summary of achievements
The culture of drug development has changed following the imple-
mentation of legislation in the EU and US. Regulators, industry and inves-
tigators have developed a system that routinely delivers development
plans to guide research and product label changes to guide clinical
practice.
There is more attention to the needs of children than there was in
the past. There is more attention to formulations, extrapolation and off
patentmedicines than there was in the past. The data from the agencies
and others provides encouragingmarkers about the process. There have
been signiﬁcant advances in regulatory science as evidenced by the
ongoing publication of guidance documents.5. Problems and lessons learned
Stakeholders have identiﬁed a number of issues and points for
further process development. These include:
• Industry, regulators, investigators and advocates for children and
young people need to work closely during the development of paedi-
atric development plans.
○ This is particularly important when a large number of molecules
are under development for a high impact condition with a small
patient group (e.g. Type 2 Diabetes and Hepatitis C, pulmonary
hypertension, arterial hypertension, and HIV infection).
• Although there has been progress with including neonates in drug de-
velopment there is still a way to go [70–72]. In part, this reﬂects the
limitations of incentives and poor market signals for this age group.
There remains a market failure for research in neonates. In older age
groups the legislation has shown that it is possible to overcome
market failure.
• The therapeutic areas covered by studies conducted under the legisla-
tion reﬂect the adult needs rather than children's needs [16,19]. It has
been suggested that there is a need to measure PIPs against a bench-
mark of paediatric needs. However, it may be difﬁcult to identify a
suitable benchmark.
• Long term safety and effectiveness remain under studied. New EU
pharmacovigilance legislation as well as incorporation of relevant as-
sessments in longitudinal studies in children may help. The FDASIA
also addresses this point.
• The US Government and EU have made signiﬁcant investment in
research about off patent medicines. In Europe PUMA has stimulated
research through EU funding but so far has notmademuch difference
to licensing.5.1. Conduct of development plans
Somedevelopment plans are easier than others. The IoM report con-
sidered the case study of treatments for HIV infection, bacterial conjunc-
tivitis and gastro-oesophageal reﬂux (GOR) in neonates. Successful drug
development was associated with (1) clarity and agreement about the
nature of the condition to be studied; (2) valid, reliable, and practical
methods to diagnose the condition and account for the heterogeneity
of the population; and (3) valid and reliable endpoints for studies of re-
sponse or efﬁcacy [19]. As further examples, FDA has reported factors
associated with successful trials in migraine [54]. The EMA has
described development programmes for pain [70].
Delays occur in paediatric drug development. These are most
frequently due to recruitment. This may be improved by better
feasibility. The ideal approach is to design the drug development
programme around a realistic assessment of the number of pa-
tients available for research. Networks can contribute to this but
this process needs to be formalized. The second important cause
of delays is regulatory process. This needs more harmonisation.
The burden of regulation needs to be minimised. Many large
pharmaceutical companies have strong paediatric teams. Greater
understanding of paediatric drug development and regulatory
processes is needed particularly among small companies and aca-
demic investigators. It is noteworthy that concerns about safety
and efﬁcacy of medicines were relatively rare causes of delay,
reported in less than 5% of plans available for assessment (see
Section 5.5 above). This preliminary evidence that fears about
exposing children to medicines during the development of the
medicine may be unfounded. Other causes for studies not achiev-
ing their full potential noted in the IoM report include a lack of
dose ranging studies to guide efﬁcacy trials. The agencies are
working on this problem including the intelligent application of
simulation and modeling.
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It is clear that companies have rarely used existing data to update la-
bels. It is striking that of the 18,000 studies reported to the EMA under
Article 45 of the regulation, very few are of sufﬁcient quality to support
changes to labels. This raises important questions about the ability of in-
vestigators (in industry and clinical settings) to design and conduct
studies. This situation needs to improve. The following observation is
striking: “It is disappointing, and perhaps surprising for the [EMA's
Paediatric] Committee, that many healthcare professionals do not rec-
ognise the need for evidence based paediatric prescribing, achieved
through the conduct of paediatric clinical trials [73]”. The EMA PDCO
considers that this unexpected hurdle should be addressed by all stake-
holders. Indeed, ICH E11 notes that the “responsibility is shared by
companies, regulatory authorities, health professionals, and society as
a whole”.
5.3. Application of ﬁndings
Newdata about pediatricmedicines has not been diffused adequate-
ly. For example, between 1998 and 2004 253 studies were submitted to
the FDA to support pediatric exclusivity, only 113 (45%)were published
in the peer reviewed literature [74]. Safety data is under represented in
publications [75]. This indicates a need to develop knowledge transla-
tion processes to ensure the effective implementation of the
information that is gathered during drug development.
Hoppu et al. examined the impact of changes in marketing autho-
risations in the EU and US on medicines available in other regions of
the world. They describe the situation as a “hostage” environment in
which children across the world contribute to research that is reﬂected
in prescribing information in the EU and US but not in all the countries
that contribute to the research [15].
5.4. Waivers
One reason for unmet needs is the way the waiver system has been
applied. Both PREA and the EU Regulation only required studies in chil-
drenwhen drugswere developed for adult indications andwhen the in-
dication was the same in children and adults. In addition, when drugs
are developed for indications only seen in children then development
is required. However, there has been a loophole. When drugs are devel-
oped for adult indications but the drugs can be applied in other condi-
tions in children, development is not required. This has led to some
signiﬁcant clinical needs being ignored. Waivers from paediatric devel-
opment need to be based on whether a drug has any application in
children. EMA is looking for ways to correct this problem [76]. In the
US, the incentive programme under BPCA can still apply but it remains
voluntary.
5.5. Ethics
Some of the ethical issues in paediatric drug development need con-
tinued discussion. In February 2008, the European Commission released
an updated recommendation on ethical aspects of clinical trials involv-
ing children to tackle the weakness of the existing rules by integrating
principles contained in other various international ethical/legal sources
with the aim of ensuring the protection of subjects involved in biomed-
ical research, while recognizing the importance of beneﬁts derived from
research [77]. However, there is always a need to balance interests of
the individual with beneﬁts of more knowledge. This discussion needs
to be rooted in the speciﬁcs of each development programme. There is
no escaping dialogue between families, investigators, regulators, indus-
try and Ethics Committees as early as possible and frequently during the
planning and implementation of development plans. One particular
sticking point in discussions has been the choice of comparator when
the standard of care involves off label use of a medicine.In Europe, at least, Ethics Committees are not well positioned to deal
with studies needed under the Paediatric Regulation [78]. Issues identi-
ﬁed by Ethics Committees following the introduction of the European
Regulation included a need for more expertise in evaluating clinical
trial protocols, particularly inclusion and exclusion criteria, difﬁculty in
understanding measures to minimize pain and discomfort among chil-
dren participating in trials and complexity in evaluating consent/assent
and the risk/beneﬁt balance of trials [78].
5.6. Animals
The utility of studies in juvenile animals during paediatric drug
development has been discussed in a number of reviews [41,42,79–83].
Given the conﬁdentiality that surrounds these studies it is difﬁcult to
make a systematic assessment of the contribution to drug development
by research involving juvenile animals. A surveywithin industry includ-
ed 82 development programmes from 11 companies through to 2009
[79].
Key points include the need to continue developing studies focused
on speciﬁc questions relevant to children, rather than apply standard
toxicology designs to juvenile animals, and the need for consistent ad-
vice between regulatory authorities (supported by early engagement
between sponsors, regulators and investigators). The scope of work in-
volving juvenile animals may change with the development of: greater
understanding of postnatal adaptation in all species; greater under-
standing of correlations between species; microsampling toxicokinetic
methodologies and post-marketing surveillance in humans. It may be
possible to reduce testing of drugs in the same class once the develop-
mental safety proﬁle has been established in one example of that class.
5.7. Impact of the legislation
It is difﬁcult to identify the effects of the legislation onmedicine uti-
lization (or even prescriptions) due to problems with the data that is
available. A more developed picture of the situation would require
extra data to be collected by health care systems, industry and regula-
tors. It is not clear where the resources to do this can be found.
Some pediatric development plans have been submitted to regula-
tors that are relatively late in the life cycle of the drug. From the
perspective of the regulators, these delays appear to result frommisun-
derstanding the needs of and opportunities provided by legislation.
Some authors argue that the situation would be improved if the EU
and US harmonise their requirements.
The IoM report suggested that administrative burdens need to be
reduced while the transparency of decisions and justiﬁcations for deci-
sions needs to be increased [19]. Access to data is important for system-
atic reviews [84].
The regulatory initiatives have led to drug development programmes
that incur signiﬁcant costs. It will be important to justify those costs. The
primary justiﬁcation for these initiatives has been the improvements in
child health that will follow from greater availability of medicines with
a marketing authorisation. It is important to assess whether the legisla-
tion is having the intended effects.
A direct evaluation of the impact of efforts to improve the availability
ofmedicineswith amarketing authorisation can be envisaged. Themost
direct approach would be to identify clinical needs that were not ad-
dressed before the advent of the legislation and determine the extent
to which those needs are met after the legislation was introduced,
with a sufﬁcient delay to allow drug development and market penetra-
tion. A cost utility analysiswould be required for each clinical need. Each
clinical needwould require speciﬁc assessments of health status among
children to be captured at baseline and after sufﬁcient time for the leg-
islation to have an effect. This requires that relevant measures of health
status were available and utilized in the decade before 2005 and will be
reapplied to a similar population in the decade after 2015. Accurate
costing data for the drug development programme would be needed.
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a few informative case studies but the direct approach is unlikely to be
sufﬁcient to make a deﬁnitive evaluation of the direct public health
impact of the legislation.
In the context of imperfect information indirect measures will be
needed. Process metrics will be valuable. A number of process metrics
have been summarised in Section 4 of this review. One importantmetric
is the proportion of prescriptions that are supported by adequate label-
ing information. Baseline data is available for some clinical areas in
many settings [85].
The legislation supports a company to obtain amarketing authorisa-
tion or labeling update for a speciﬁc medicine for a speciﬁc indication.
This step is only one part of the link between medicines and child
health. Once a marketing authorisation has been approved a number
of steps that are required before themedicine can have the intended ef-
fect. These include: obtaining patent and other beneﬁts under the legis-
lation; inﬂuencing health care reimbursers to allow the medicine to be
used; inﬂuencing prescribers to prescribe the medicine; and ensuring
sufﬁcient adherence for themedicine to have an effect. Successful appli-
cation of the legislation will therefore need a number of “downstream”
events to fall into place. An apparent lack of effect may reﬂect down-
stream issues rather than problems with the legislation.
A further consideration is the framework used for the evaluation of
the legislation. Monetary cost is one frame of reference but is not the
only one. Patient preference is important. In addition there is a moral
dimension. The regulatory changes that followed the sulphanilamide
or thalidomide disasters were not based on ﬁnancial calculation. The
problems spoke for themselves.
In summary, an assessment of the impact of the legislation on child
health should be multimodal. When speciﬁc case studies of success or
failure can be identiﬁed they should be evaluated in detail. Processmet-
rics will be important. A narrative approach that takes account of attri-
tion during and after drug development will be informative. It should
be recognised that a rigorous assessment will be costly. The data neces-
sary for the evaluation of the legislation is not the same as the data
needed for the implementation of the legislation. There will need to
be a balance between the rigor and cost of the evaluation. Groundwork
to support an evaluation could include gathering selected baseline data
and debating the terms of reference for the evaluation.
6. Work by networks and investigators to apply the framework for
drug development in children
Efﬁcient drug development requires close working between regula-
tors, industry and investigators. As noted, investigators work best in
clinical research networks. The EuropeanCommission has funded aNet-
work of Excellence to bring together networks and the EMA to optimise
drug development in children. This network, Global Research in Paedi-
atrics, GRiP, is working on a number of themes http://tinyurl.com/
ozv863z.
6.1. Education and training
The people involved in medicine development need to have appro-
priate knowledge and skills about the scientiﬁc and regulatory stan-
dards and expectations. This includes children and young people, their
parents and families. Generic training to support patient and public
involvement is available: EuPATI: http://tinyurl.com/c5yxk5e.
Professionals also need education and training. This can be generic,
such as Good Clinical Practice (GCP). There is a need to address the spe-
ciﬁc issues that arise during research with children. GRiP is addressing
these issues with a palette of training opportunities. These include a 1
or 2 day road show that is designed to introduce the issues to profes-
sionals involved in children's medicine research. GRiP is also organising
a Masters course in Pharmacology and Clinical Trials in Children.This will be supplemented by speciﬁc tools to support the evaluation
of medicines in children.
6.2. Post-marketing surveillance
The formal evaluation of medicines, usually before an indication is
granted, is limited in scope and does not include enough children to
identify the nature or extent of important concerns with the safety of
medicines. Post-marketing surveillance is an essential part of the
lifecycle of medicines. A large amount of information is captured in rou-
tine clinical databases and can contribute to post-marketing surveil-
lance. One important challenge is unlocking this information and
making it available for analysis. GRiP is working on approaches to
linking clinical databases. This work includes software that can bridge
between proprietary database structures and governance systems that
allow data to be shared while respecting legal and other requirements.
6.3. Interoperability & infrastructure
Medicine evaluation currently involvesmany people doing the same
thing in different ways. The drug development community needs to en-
sure that study assessments yield comparable data and that data can be
shared. This requires attention to shared terminology. GRiP is working
with a range of study teams to develop shared terminology for clinical
studies. This will allow consistent assessments and data sharing. In ad-
dition, many study procedures have been optimized in some settings
and provide useful templates for work more generally.
Infrastructure is another issue to be taken into account and in this
sense, some attempts have been made by the European Network of
Paediatric Research set-up at the EMA (Enpr-EMA) and expected to fa-
cilitate capacity building and bringing together national and European
networks, investigators and centres with speciﬁc expertise in design
and conduct of paediatric studies: http://tinyurl.com/pwnlgqt.
6.4. New methods
“Conventional” approaches to medicine development may be sub-
optimal for some novel therapies in some age groups [86]. There is a
need to develop medicines as efﬁciently and quickly as possible, partic-
ularly for serious conditions affecting children [87]. This requires a
range of methodologies that can be used as the situation requires.
These considerations apply to children, even more than adults. GRiP is
evaluating a range of novel methodologies to facilitate the rational se-
lection ofmethodologies in the contemporary landscape for therapeutic
development.
6.5. Formulations
Children deserve age-appropriate formulations. Formulation devel-
opment is a relatively poorly developed area. It lies at the interface be-
tween hypothesis-driven research and technology. The current need is
to build up capacity and share expertise. GRiP is working to establish
and maintain an International Paediatric Formulation Knowledge
Platform; provide formulation education for scientists and clinicians;
and facilitate global paediatric formulation research worldwide.
6.6. Neonates
Neonatology has traditionally been a research rich specialty. That re-
search has not been linked to the work required to obtain marketing
authorisations of medicines for newborn babies. GRiP is undertaking
underpinning work to facilitate links between research activity and
therapeutic development.
The effects of medicines may not be apparent immediately, particu-
larly in neonates. Medicines may inﬂuence developmental processes
that underpin physiological or psychological function that is only
11M.A. Turner et al. / Advanced Drug Delivery Reviews 73 (2014) 2–13manifested years after amedicine is given.Medicinesmay have beneﬁts
or harms during infancy, which are not translated into important out-
comes later in life [88,89]. Interventions may have beneﬁts or harms
that are only apparent in later life [90]. Long-term follow-up can provide
reassurance about concerns derived from studies of animals [91]. One
approach to these issues is to insist that all neonatal drug developments
include follow-up until outcomes can be reliably ascertained. For
neurocognitive outcomes this will be at school age or older [92]. For
renal, cardiovascular or pulmonary outcomes this may be into adult-
hood [93,94]. Short-term beneﬁts may be sufﬁcient to justify a market-
ing authorisation so that long-term follow-upmay not be appropriate in
all cases. Conditional authorisation will be a useful mechanism. In any
case drug development plans can only be developed in the light of the
start of the art. The understanding of development, and its assessment,
may change over time. Deﬁnitive judgments about licensing/marketing
authorisation need to relate to the state of the art when the programme
was planned. Themarket (reimbursers and prescribers) is the best place
to decide whether themedicine should be used in the light of the infor-
mation available at the time of use.
When long-term outcomes are necessary for marketing authorisa-
tion or post-marketing surveillance, one approach is to ensure that ne-
onates are tracked in sufﬁcient detail to allow long-term surveillance.
The costs of tracking and generic assessments should be borne by health
care systems since long-term follow-up of sick neonates has generic
value: long-term follow-up informs service delivery as well as drug de-
velopment. When speciﬁc risks can be foreseen on the basis of known
biology or preclinical/clinical drug development then additional, specif-
ic assessment of these anticipated harms could be organised by research
networks and paid for by whoever will beneﬁt from the information
(e.g. sponsor). It is important to remember that neonatal markets
have limited ﬁnancial value and it is important to avoid pricing innova-
tors out of the market. The recovery of costs associated with long-term
surveillance requires careful negotiation and is likely to require
arrangements that share risk between health care systems and phar-
maceutical companies. The costs and effort for families and clinicians
will be minimised by agreement about the content and timing of
assessments. Standardised outcome assessments will also allow
pooling of data which will maximise the value of information gained
during research.
6.7. General issues
A common approach underlines much of this work. Assessment is
followed by evaluation leading to the development of deliverables. As-
sessment includes the design of a research question that is used to con-
duct an environmental scan and/or a systematic review. Evaluation
involves combining the results of the assessment phase with novelA Knowledge Advancement Process 
1. Initial Assessment Phase
1.1. Research Topic Identification
1.2. Environmental Scan
1.3. Systematic Review
2. Evaluation Phase
2.1. Draft knowledge summary
2.2. Gap Analysis
2.3. Consultation with stakeholders and subject matter experts
3. Experimental or Simulation Phase
3.1. Generate new data if needed and feasible
4. Consensus Phase
4.1. Second draft incorporating consultation and new data
4.2. Conference or dissemination to select individuals and organizations
5. Final draft
5.1. Dissemination and Knowledge Transfer
Fig. 1. A knowledge advancement process.work by GRiP partners. This leads to iterative reﬁnement of draft out-
puts. The drafts are inﬂuenced by appraisals, Delphi processes, surveys
and application to real world situations as appropriate. The material is
then presented as deliverables. The aim is to provide materials that
are ﬁt for purpose, targeted for speciﬁc needs while avoiding duplicate
effort. GRiP developed a general inquiry approach that involves sequen-
tial surveys of publications and individuals to generate a description of
the current status of a topic. The current status is then subject to a gap
analysis for what key data or concepts are barriers or lacking. Following
identiﬁcation of knowledge gaps, small studies are designed speciﬁcally
to address the gaps. Subsequently, the gap-ﬁlling data are reintegrated
into the larger summary status and the whole is analysed again by sub-
ject matter experts (See Fig. 1).
The diverse components of GRiP all address a common aim: to de-
velop an infrastructurematrix that facilitates the development of appro-
priate medicines for children. The GRiP network provides a strong
model for the integration of these efforts. Another commonality relates
to the challenges inherent in the implementation of that matrix. Devel-
oping medicines requires coordination between regulators, industry,
patients and investigators. A challenge for investigators is aligning
their work to the expectations of regulators and industry. This involves
working to the stringency required for regulatory processes. Many
clinical investigators are used to working to academic standards or the
standards required to inﬂuence their peers. These standards are differ-
ent from the standards required for regulatory approval. Regulatory
standards are informed by a long history of therapeutic disasters and
the potential for commercial pressures to inﬂuence the design and in-
terpretation of studies [3]. These inﬂuences translate into greater rigor
and stringency in the regulatory approach than other approaches to re-
search about medicine in children. The GRiP project, and other projects
funded by the European Commission will raise the awareness of the re-
quirements for regulatory approval of medicines for children [95]. This
will have spin off effects by exposing clinical researchers to a range of
designs and higher standards for data collection and analysis. Increased
rigor in studies that are not aimed at regulatory submissionswill reduce
the risk of bias and increase the utility of studies about medicines for
children.
7. Conclusions
The time is ripe for a concerted effort to improve the therapies avail-
able for children. After decades of effort the regulatory frameworks for
the rational development of medicines for children were put in place
in recent years. These frameworks have now been road tested and can
be used with conﬁdence. GRiP and other initiatives are deﬁning how
to make the most of the opportunities provided by the established
frameworks for paediatric drug development.
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